Saturday 17 October 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
141.10
2.33
+1.68%
Follow PODD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
9 | 6 | 6 | 6 |
+8 more TTM periods Free account |
| 26.02% | 23.00% | 18.12% | 19.68% | ||
| 11.31% | 9.31% | 7.87% | 8.13% | ||
ROIC |
17.56% | 17.90% | 16.94% | 16.64% | |
Return on Tangible Assets |
19.11% | 16.35% | 12.03% | 12.72% | |
Average Days of Receivables |
70.37 | 68.54 | 69.67 | 66.90 | |
Free Cash Flow per Share |
3.83 | 5.54 | 4.97 | 5.79 | |
Free Cash Flow |
265.60 | 387.80 | 349.90 | 407.50 | |
Capital Expenditures |
(245.60) | (231.50) | (219.40) | (126.00) | |
| Other line items | |||||
Cash ROIC |
9.14% | 14.20% | 11.00% | 12.91% | |
Accounts Receivable Turnover |
5.91 | 6.13 | 6.14 | 6.02 | |
Accounts Payable Turnover |
8.05 | 8.11 | 16.21 | 16.26 | |
Inventory Turnover |
1.90 | 1.86 | 1.74 | 1.61 | |
Average Days of Payables |
50.96 | 65.01 | 35.64 | 24.45 | |
Days of Inventory on Hand |
200.35 | 200.73 | 215.05 | 226.38 | |
Tax Rate |
(0.24) | (0.25) | (0.27) | (0.21) | |
Research and Development Expense of Revenue |
11.33% | 11.42% | 11.12% | 10.74% | |
Selling, General and Administrative Expense of Revenue |
42.86% | 42.11% | 43.02% | 43.40% | |
Share Based Compensation of Revenue |
2.55% | 2.27% | 2.32% | 2.47% | |
Interest Coverage |
8.77 | 7.81 | 7.98 | 8.25 | |
Operating CF/Net income |
1.36 | 2.05 | 2.30 | 2.17 | |
Depreciation/Fixed assets |
0.12 | 0.11 | 0.11 | 0.12 | |
Capex/Depreciation |
(2.47) | (2.44) | (2.43) | (1.44) | |
Revenue per Share |
44.06 | 41.45 | 38.50 | 35.84 | |
Operating CF per Share |
7.38 | 8.85 | 8.09 | 7.58 | |
Capex per Share |
(3.54) | (3.31) | (3.12) | (1.79) | |
Capex to Sales |
0.08 | 0.08 | 0.08 | 0.05 |
Columns are period end dates